1 min read · 02 December 2009
Vizu Corporation, a San Francisco-based online ad platform provider, raised a $6.75M round of financing co-lead by iNovia Captial and Greycroft Partners with participation from existing investors including Draper Fisher Jurvetson and Esther Dyson.
3 min read · 02 December 2009
Aravo, a supplier information management business, closed a $27 million Series D financing round with Cisco as a new strategic investor and the largest participant in the round. The $27 million Series D financing brings Aravo’s total investment to $50 million. The Cisco strategic investment represents Aravo’s first institutional investment, with all prior financing provided by individuals. Previous investors include Charles Schwab/Big Sky Partners and Stephen Friedman.
3 min read · 02 December 2009
gWallet, a San Francisco-based monetization platform for social media, has raised $10 million in Series A funding. Adams Street Partners and Trinity Ventures led the round, which brings gWallet's total funding to $12.5 million.
4 min read · 01 December 2009
Alfred Macdaniel has joined Santé Ventures as vice president of finance and general counsel. He previously was a senior associate with Fish & Richardson PC.
1 min read · 01 December 2009
Horizon Data Center Solutions, a Plano, Texas-based data center and IT flexsourcing firm, has raised $7.5 million in VC funding led by Ballast Point Ventures.
3 min read · 01 December 2009
Innotech Solar AS, a Navrik, Norway-based company focused on increasing the effectiveness of solar cells, has raised approximately $9.6 million in VC funding from Investinor and company employees.
2 min read · 01 December 2009
Covagen AG, a Zurich-based developer of a novel class of protein therapeutics, has secured an undisclosed amount of seed funding from Ventech.
3 min read · 01 December 2009
Aquantia Corp., a Milpitas, Calif.-based developer of physical-layer transceiver ICs, has secured $35 million of a Series D round that ultimately could be worth $44 million. New Enterprise Associates led the round, and was joined by return backers Lightspeed Venture Partners, Greylock Partners, Pinnacle Ventures and Venture Tech Alliance. Aquantia previously raised around $40 million.
3 min read · 01 December 2009
FORMA Therapeutics, a Cambridge, Mass.-based small molecule drug developer with an initial focus on cancer, has raised $25.5 million in Series B funding. Lilly Ventures led the round, and was joined by return backers Novartis Option Fund and Bio*One Capital. The company previously raised $25 million.
3 min read · 01 December 2009
